Biomerica, Inc. (BMRA) - 10-K Summary
Business Context and Reporting Period
Company: Biomerica, Inc.
Filing Type: Form 10-K (Annual Report)
Fiscal Year Ended: May 31, 2011
Business Overview: Biomerica develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care settings (physicians' offices and over-the-counter). Products include tests for chronic diseases, hormones, and antibodies. The company operates manufacturing facilities in Irvine, California, and Mexicali, Mexico. In July 2010, the company eliminated its internal research department to focus on licensing external technology.
Key Financial Metrics
| Metric | Fiscal 2011 | Fiscal 2010 |
|---|---|---|
| Net Sales | $4,899,375 | $5,075,222 |
| Gross Profit | $1,525,589 | $1,560,767 |
| Gross Margin | 31.1% | 30.8% |
| Net Income (Loss) | $157,447 | $(331,455) |
| Operating Loss | $(132,261) | $(364,520) |
| Cash and Cash Equivalents | $989,270 | $1,055,206 |
| Working Capital | $3,261,418 | $3,176,438 |
| Debt (Current Portion) | $35,390 | $45,075 |
| Debt (Long-Term) | $0 | $35,424 |
Revenue by Geography (2011): Europe (50.7%), United States (23.7%), Asia (23.5%).
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 3.5% to $4.90 million. While U.S. sales increased by approximately $109,000 (driven by a major chain drug store), this was offset by a decline in Asian sales due to sales incentives and new product registration costs.
- Profitability Turnaround: The company reported a net income of $157,447 in 2011, reversing a net loss of $331,455 in 2010. This turnaround was primarily driven by a non-recurring government grant.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses decreased 15.8% to $1.24 million. This reduction was largely due to the absence of $225,000 in moving expenses incurred in 2010 and an $80,000 reduction in accrued vacation expense related to a settlement with a former CEO's estate.
- Other Income: Other income surged to $290,170 from $17,675, primarily due to a $285,969 net gain from a Qualifying Therapeutic Discovery Project grant.
Guidance, Outlook, and Risks
Management Commentary: Management continues to pursue a strategy of licensing technology rather than internal R&D to accelerate product time-to-market. The company has invested in new product licenses and a distributor in Poland ($165,324).
Liquidity: The company maintains a $400,000 line of credit with Union Bank, which was renewed in June 2011. No amounts were drawn on this line as of May 31, 2011. Cash provided by operations was $328,803, a significant improvement from the $236,980 cash used in 2010.
Risks and Contingencies:
- Customer Concentration: One customer accounted for 22.2% of total sales in 2011. The loss of this distributor could materially impact results.
- Regulatory Compliance: Products are subject to FDA and international regulations. Failure to maintain compliance could result in fines, recalls, or suspension of production.
- Raw Materials: The company relies on a limited number of suppliers for critical raw materials (e.g., antibodies), creating supply chain risks.
- Stock Liquidity: The stock trades on the OTC Bulletin Board with limited liquidity.
Investor Verification Checklist
- Grant Sustainability: Verify the sustainability of the $286k government grant that drove the 2011 net income, as operating income remained negative ($132k loss).
- Customer Concentration: Assess the stability of the relationship with the single customer representing 22.2% of sales.
- Asian Market Recovery: Monitor the recovery of sales in Asia, which declined due to incentives and registration costs.
- Debt Covenants: Review the terms of the $400k line of credit, specifically the requirement to maintain a zero balance for 30 consecutive days annually.
- Inventory Levels: Review inventory reserves for obsolescence, given the shift in strategy from internal R&D to licensing.